Global Neulasta (Pegfilgrastim) and Biosimilar Supply, Demand and Key Producers, 2023-2029
The global Neulasta (Pegfilgrastim) and Biosimilar market size is expected to reach $ 3816.3 million by 2029, rising at a market growth of 6.2% CAGR during the forecast period (2023-2029).
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
This report studies the global Neulasta (Pegfilgrastim) and Biosimilar production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Neulasta (Pegfilgrastim) and Biosimilar, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Neulasta (Pegfilgrastim) and Biosimilar that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Neulasta (Pegfilgrastim) and Biosimilar total production and demand, 2018-2029, (K Units)
Global Neulasta (Pegfilgrastim) and Biosimilar total production value, 2018-2029, (USD Million)
Global Neulasta (Pegfilgrastim) and Biosimilar production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Neulasta (Pegfilgrastim) and Biosimilar consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Neulasta (Pegfilgrastim) and Biosimilar domestic production, consumption, key domestic manufacturers and share
Global Neulasta (Pegfilgrastim) and Biosimilar production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Neulasta (Pegfilgrastim) and Biosimilar production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Neulasta (Pegfilgrastim) and Biosimilar production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Neulasta (Pegfilgrastim) and Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Viatris, Coherus, Novartis, Pfizer, Amneal Pharmaceutical and Fresenius Kabi, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Neulasta (Pegfilgrastim) and Biosimilar market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Neulasta (Pegfilgrastim) and Biosimilar Market, By Region:
1. How big is the global Neulasta (Pegfilgrastim) and Biosimilar market?
2. What is the demand of the global Neulasta (Pegfilgrastim) and Biosimilar market?
3. What is the year over year growth of the global Neulasta (Pegfilgrastim) and Biosimilar market?
4. What is the production and production value of the global Neulasta (Pegfilgrastim) and Biosimilar market?
5. Who are the key producers in the global Neulasta (Pegfilgrastim) and Biosimilar market?
6. What are the growth factors driving the market demand?
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
This report studies the global Neulasta (Pegfilgrastim) and Biosimilar production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Neulasta (Pegfilgrastim) and Biosimilar, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Neulasta (Pegfilgrastim) and Biosimilar that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Neulasta (Pegfilgrastim) and Biosimilar total production and demand, 2018-2029, (K Units)
Global Neulasta (Pegfilgrastim) and Biosimilar total production value, 2018-2029, (USD Million)
Global Neulasta (Pegfilgrastim) and Biosimilar production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Neulasta (Pegfilgrastim) and Biosimilar consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Neulasta (Pegfilgrastim) and Biosimilar domestic production, consumption, key domestic manufacturers and share
Global Neulasta (Pegfilgrastim) and Biosimilar production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Neulasta (Pegfilgrastim) and Biosimilar production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Neulasta (Pegfilgrastim) and Biosimilar production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Neulasta (Pegfilgrastim) and Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Viatris, Coherus, Novartis, Pfizer, Amneal Pharmaceutical and Fresenius Kabi, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Neulasta (Pegfilgrastim) and Biosimilar market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Neulasta (Pegfilgrastim) and Biosimilar Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Brand
- Biosimilar
- Hospital
- Pharmacy
- Other
- Amgen
- Viatris
- Coherus
- Novartis
- Pfizer
- Amneal Pharmaceutical
- Fresenius Kabi
1. How big is the global Neulasta (Pegfilgrastim) and Biosimilar market?
2. What is the demand of the global Neulasta (Pegfilgrastim) and Biosimilar market?
3. What is the year over year growth of the global Neulasta (Pegfilgrastim) and Biosimilar market?
4. What is the production and production value of the global Neulasta (Pegfilgrastim) and Biosimilar market?
5. Who are the key producers in the global Neulasta (Pegfilgrastim) and Biosimilar market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Neulasta (Pegfilgrastim) and Biosimilar Introduction
1.2 World Neulasta (Pegfilgrastim) and Biosimilar Supply & Forecast
1.2.1 World Neulasta (Pegfilgrastim) and Biosimilar Production Value (2018 & 2022 & 2029)
1.2.2 World Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029)
1.2.3 World Neulasta (Pegfilgrastim) and Biosimilar Pricing Trends (2018-2029)
1.3 World Neulasta (Pegfilgrastim) and Biosimilar Production by Region (Based on Production Site)
1.3.1 World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Region (2018-2029)
1.3.2 World Neulasta (Pegfilgrastim) and Biosimilar Production by Region (2018-2029)
1.3.3 World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Region (2018-2029)
1.3.4 North America Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029)
1.3.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029)
1.3.6 China Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029)
1.3.7 Japan Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Neulasta (Pegfilgrastim) and Biosimilar Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Neulasta (Pegfilgrastim) and Biosimilar Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Neulasta (Pegfilgrastim) and Biosimilar Demand (2018-2029)
2.2 World Neulasta (Pegfilgrastim) and Biosimilar Consumption by Region
2.2.1 World Neulasta (Pegfilgrastim) and Biosimilar Consumption by Region (2018-2023)
2.2.2 World Neulasta (Pegfilgrastim) and Biosimilar Consumption Forecast by Region (2024-2029)
2.3 United States Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.4 China Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.6 Japan Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.7 South Korea Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.8 ASEAN Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.9 India Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
3 WORLD NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Manufacturer (2018-2023)
3.2 World Neulasta (Pegfilgrastim) and Biosimilar Production by Manufacturer (2018-2023)
3.3 World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Neulasta (Pegfilgrastim) and Biosimilar Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Neulasta (Pegfilgrastim) and Biosimilar Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Neulasta (Pegfilgrastim) and Biosimilar in 2022
3.5.3 Global Concentration Ratios (CR8) for Neulasta (Pegfilgrastim) and Biosimilar in 2022
3.6 Neulasta (Pegfilgrastim) and Biosimilar Market: Overall Company Footprint Analysis
3.6.1 Neulasta (Pegfilgrastim) and Biosimilar Market: Region Footprint
3.6.2 Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Type Footprint
3.6.3 Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Value Comparison
4.1.1 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Comparison
4.2.1 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Consumption Comparison
4.3.1 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value (2018-2023)
4.4.3 United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023)
4.5 China Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers and Market Share
4.5.1 China Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value (2018-2023)
4.5.3 China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023)
4.6 Rest of World Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Neulasta (Pegfilgrastim) and Biosimilar Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Brand
5.2.2 Biosimilar
5.3 Market Segment by Type
5.3.1 World Neulasta (Pegfilgrastim) and Biosimilar Production by Type (2018-2029)
5.3.2 World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Type (2018-2029)
5.3.3 World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Neulasta (Pegfilgrastim) and Biosimilar Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Pharmacy
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Neulasta (Pegfilgrastim) and Biosimilar Production by Application (2018-2029)
6.3.2 World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Application (2018-2029)
6.3.3 World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Amgen
7.1.1 Amgen Details
7.1.2 Amgen Major Business
7.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.1.4 Amgen Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Amgen Recent Developments/Updates
7.1.6 Amgen Competitive Strengths & Weaknesses
7.2 Viatris
7.2.1 Viatris Details
7.2.2 Viatris Major Business
7.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.2.4 Viatris Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Viatris Recent Developments/Updates
7.2.6 Viatris Competitive Strengths & Weaknesses
7.3 Coherus
7.3.1 Coherus Details
7.3.2 Coherus Major Business
7.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.3.4 Coherus Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Coherus Recent Developments/Updates
7.3.6 Coherus Competitive Strengths & Weaknesses
7.4 Novartis
7.4.1 Novartis Details
7.4.2 Novartis Major Business
7.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.4.4 Novartis Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Novartis Recent Developments/Updates
7.4.6 Novartis Competitive Strengths & Weaknesses
7.5 Pfizer
7.5.1 Pfizer Details
7.5.2 Pfizer Major Business
7.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.5.4 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Pfizer Recent Developments/Updates
7.5.6 Pfizer Competitive Strengths & Weaknesses
7.6 Amneal Pharmaceutical
7.6.1 Amneal Pharmaceutical Details
7.6.2 Amneal Pharmaceutical Major Business
7.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.6.4 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Amneal Pharmaceutical Recent Developments/Updates
7.6.6 Amneal Pharmaceutical Competitive Strengths & Weaknesses
7.7 Fresenius Kabi
7.7.1 Fresenius Kabi Details
7.7.2 Fresenius Kabi Major Business
7.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.7.4 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Fresenius Kabi Recent Developments/Updates
7.7.6 Fresenius Kabi Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Chain
8.2 Neulasta (Pegfilgrastim) and Biosimilar Upstream Analysis
8.2.1 Neulasta (Pegfilgrastim) and Biosimilar Core Raw Materials
8.2.2 Main Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Neulasta (Pegfilgrastim) and Biosimilar Production Mode
8.6 Neulasta (Pegfilgrastim) and Biosimilar Procurement Model
8.7 Neulasta (Pegfilgrastim) and Biosimilar Industry Sales Model and Sales Channels
8.7.1 Neulasta (Pegfilgrastim) and Biosimilar Sales Model
8.7.2 Neulasta (Pegfilgrastim) and Biosimilar Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Neulasta (Pegfilgrastim) and Biosimilar Introduction
1.2 World Neulasta (Pegfilgrastim) and Biosimilar Supply & Forecast
1.2.1 World Neulasta (Pegfilgrastim) and Biosimilar Production Value (2018 & 2022 & 2029)
1.2.2 World Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029)
1.2.3 World Neulasta (Pegfilgrastim) and Biosimilar Pricing Trends (2018-2029)
1.3 World Neulasta (Pegfilgrastim) and Biosimilar Production by Region (Based on Production Site)
1.3.1 World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Region (2018-2029)
1.3.2 World Neulasta (Pegfilgrastim) and Biosimilar Production by Region (2018-2029)
1.3.3 World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Region (2018-2029)
1.3.4 North America Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029)
1.3.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029)
1.3.6 China Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029)
1.3.7 Japan Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Neulasta (Pegfilgrastim) and Biosimilar Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Neulasta (Pegfilgrastim) and Biosimilar Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Neulasta (Pegfilgrastim) and Biosimilar Demand (2018-2029)
2.2 World Neulasta (Pegfilgrastim) and Biosimilar Consumption by Region
2.2.1 World Neulasta (Pegfilgrastim) and Biosimilar Consumption by Region (2018-2023)
2.2.2 World Neulasta (Pegfilgrastim) and Biosimilar Consumption Forecast by Region (2024-2029)
2.3 United States Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.4 China Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.6 Japan Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.7 South Korea Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.8 ASEAN Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
2.9 India Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029)
3 WORLD NEULASTA (PEGFILGRASTIM) AND BIOSIMILAR MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Manufacturer (2018-2023)
3.2 World Neulasta (Pegfilgrastim) and Biosimilar Production by Manufacturer (2018-2023)
3.3 World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Neulasta (Pegfilgrastim) and Biosimilar Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Neulasta (Pegfilgrastim) and Biosimilar Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Neulasta (Pegfilgrastim) and Biosimilar in 2022
3.5.3 Global Concentration Ratios (CR8) for Neulasta (Pegfilgrastim) and Biosimilar in 2022
3.6 Neulasta (Pegfilgrastim) and Biosimilar Market: Overall Company Footprint Analysis
3.6.1 Neulasta (Pegfilgrastim) and Biosimilar Market: Region Footprint
3.6.2 Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Type Footprint
3.6.3 Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Value Comparison
4.1.1 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Comparison
4.2.1 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Consumption Comparison
4.3.1 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value (2018-2023)
4.4.3 United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023)
4.5 China Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers and Market Share
4.5.1 China Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value (2018-2023)
4.5.3 China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023)
4.6 Rest of World Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Neulasta (Pegfilgrastim) and Biosimilar Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Brand
5.2.2 Biosimilar
5.3 Market Segment by Type
5.3.1 World Neulasta (Pegfilgrastim) and Biosimilar Production by Type (2018-2029)
5.3.2 World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Type (2018-2029)
5.3.3 World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Neulasta (Pegfilgrastim) and Biosimilar Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Pharmacy
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Neulasta (Pegfilgrastim) and Biosimilar Production by Application (2018-2029)
6.3.2 World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Application (2018-2029)
6.3.3 World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Amgen
7.1.1 Amgen Details
7.1.2 Amgen Major Business
7.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.1.4 Amgen Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Amgen Recent Developments/Updates
7.1.6 Amgen Competitive Strengths & Weaknesses
7.2 Viatris
7.2.1 Viatris Details
7.2.2 Viatris Major Business
7.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.2.4 Viatris Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Viatris Recent Developments/Updates
7.2.6 Viatris Competitive Strengths & Weaknesses
7.3 Coherus
7.3.1 Coherus Details
7.3.2 Coherus Major Business
7.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.3.4 Coherus Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Coherus Recent Developments/Updates
7.3.6 Coherus Competitive Strengths & Weaknesses
7.4 Novartis
7.4.1 Novartis Details
7.4.2 Novartis Major Business
7.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.4.4 Novartis Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Novartis Recent Developments/Updates
7.4.6 Novartis Competitive Strengths & Weaknesses
7.5 Pfizer
7.5.1 Pfizer Details
7.5.2 Pfizer Major Business
7.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.5.4 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Pfizer Recent Developments/Updates
7.5.6 Pfizer Competitive Strengths & Weaknesses
7.6 Amneal Pharmaceutical
7.6.1 Amneal Pharmaceutical Details
7.6.2 Amneal Pharmaceutical Major Business
7.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.6.4 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Amneal Pharmaceutical Recent Developments/Updates
7.6.6 Amneal Pharmaceutical Competitive Strengths & Weaknesses
7.7 Fresenius Kabi
7.7.1 Fresenius Kabi Details
7.7.2 Fresenius Kabi Major Business
7.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product and Services
7.7.4 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.7.5 Fresenius Kabi Recent Developments/Updates
7.7.6 Fresenius Kabi Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Chain
8.2 Neulasta (Pegfilgrastim) and Biosimilar Upstream Analysis
8.2.1 Neulasta (Pegfilgrastim) and Biosimilar Core Raw Materials
8.2.2 Main Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Neulasta (Pegfilgrastim) and Biosimilar Production Mode
8.6 Neulasta (Pegfilgrastim) and Biosimilar Procurement Model
8.7 Neulasta (Pegfilgrastim) and Biosimilar Industry Sales Model and Sales Channels
8.7.1 Neulasta (Pegfilgrastim) and Biosimilar Sales Model
8.7.2 Neulasta (Pegfilgrastim) and Biosimilar Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Region (2018-2023) & (USD Million)
Table 3. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Region (2024-2029) & (USD Million)
Table 4. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Region (2018-2023)
Table 5. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Region (2024-2029)
Table 6. World Neulasta (Pegfilgrastim) and Biosimilar Production by Region (2018-2023) & (K Units)
Table 7. World Neulasta (Pegfilgrastim) and Biosimilar Production by Region (2024-2029) & (K Units)
Table 8. World Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Region (2018-2023)
Table 9. World Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Region (2024-2029)
Table 10. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Neulasta (Pegfilgrastim) and Biosimilar Major Market Trends
Table 13. World Neulasta (Pegfilgrastim) and Biosimilar Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Neulasta (Pegfilgrastim) and Biosimilar Consumption by Region (2018-2023) & (K Units)
Table 15. World Neulasta (Pegfilgrastim) and Biosimilar Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Neulasta (Pegfilgrastim) and Biosimilar Producers in 2022
Table 18. World Neulasta (Pegfilgrastim) and Biosimilar Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Neulasta (Pegfilgrastim) and Biosimilar Producers in 2022
Table 20. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Neulasta (Pegfilgrastim) and Biosimilar Company Evaluation Quadrant
Table 22. World Neulasta (Pegfilgrastim) and Biosimilar Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Neulasta (Pegfilgrastim) and Biosimilar Production Site of Key Manufacturer
Table 24. Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Type Footprint
Table 25. Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Application Footprint
Table 26. Neulasta (Pegfilgrastim) and Biosimilar Competitive Factors
Table 27. Neulasta (Pegfilgrastim) and Biosimilar New Entrant and Capacity Expansion Plans
Table 28. Neulasta (Pegfilgrastim) and Biosimilar Mergers & Acquisitions Activity
Table 29. United States VS China Neulasta (Pegfilgrastim) and Biosimilar Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Neulasta (Pegfilgrastim) and Biosimilar Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Neulasta (Pegfilgrastim) and Biosimilar Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share (2018-2023)
Table 37. China Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share (2018-2023)
Table 42. Rest of World Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share (2018-2023)
Table 47. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Neulasta (Pegfilgrastim) and Biosimilar Production by Type (2018-2023) & (K Units)
Table 49. World Neulasta (Pegfilgrastim) and Biosimilar Production by Type (2024-2029) & (K Units)
Table 50. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Type (2018-2023) & (USD Million)
Table 51. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Type (2024-2029) & (USD Million)
Table 52. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Neulasta (Pegfilgrastim) and Biosimilar Production by Application (2018-2023) & (K Units)
Table 56. World Neulasta (Pegfilgrastim) and Biosimilar Production by Application (2024-2029) & (K Units)
Table 57. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Application (2018-2023) & (USD Million)
Table 58. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Application (2024-2029) & (USD Million)
Table 59. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Amgen Basic Information, Manufacturing Base and Competitors
Table 62. Amgen Major Business
Table 63. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 64. Amgen Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Amgen Recent Developments/Updates
Table 66. Amgen Competitive Strengths & Weaknesses
Table 67. Viatris Basic Information, Manufacturing Base and Competitors
Table 68. Viatris Major Business
Table 69. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 70. Viatris Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Viatris Recent Developments/Updates
Table 72. Viatris Competitive Strengths & Weaknesses
Table 73. Coherus Basic Information, Manufacturing Base and Competitors
Table 74. Coherus Major Business
Table 75. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 76. Coherus Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Coherus Recent Developments/Updates
Table 78. Coherus Competitive Strengths & Weaknesses
Table 79. Novartis Basic Information, Manufacturing Base and Competitors
Table 80. Novartis Major Business
Table 81. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 82. Novartis Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Novartis Recent Developments/Updates
Table 84. Novartis Competitive Strengths & Weaknesses
Table 85. Pfizer Basic Information, Manufacturing Base and Competitors
Table 86. Pfizer Major Business
Table 87. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 88. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Pfizer Recent Developments/Updates
Table 90. Pfizer Competitive Strengths & Weaknesses
Table 91. Amneal Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 92. Amneal Pharmaceutical Major Business
Table 93. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 94. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Amneal Pharmaceutical Recent Developments/Updates
Table 96. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 97. Fresenius Kabi Major Business
Table 98. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 99. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 100. Global Key Players of Neulasta (Pegfilgrastim) and Biosimilar Upstream (Raw Materials)
Table 101. Neulasta (Pegfilgrastim) and Biosimilar Typical Customers
Table 102. Neulasta (Pegfilgrastim) and Biosimilar Typical Distributors
Table 1. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Region (2018-2023) & (USD Million)
Table 3. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Region (2024-2029) & (USD Million)
Table 4. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Region (2018-2023)
Table 5. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Region (2024-2029)
Table 6. World Neulasta (Pegfilgrastim) and Biosimilar Production by Region (2018-2023) & (K Units)
Table 7. World Neulasta (Pegfilgrastim) and Biosimilar Production by Region (2024-2029) & (K Units)
Table 8. World Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Region (2018-2023)
Table 9. World Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Region (2024-2029)
Table 10. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Neulasta (Pegfilgrastim) and Biosimilar Major Market Trends
Table 13. World Neulasta (Pegfilgrastim) and Biosimilar Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Neulasta (Pegfilgrastim) and Biosimilar Consumption by Region (2018-2023) & (K Units)
Table 15. World Neulasta (Pegfilgrastim) and Biosimilar Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Neulasta (Pegfilgrastim) and Biosimilar Producers in 2022
Table 18. World Neulasta (Pegfilgrastim) and Biosimilar Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Neulasta (Pegfilgrastim) and Biosimilar Producers in 2022
Table 20. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Neulasta (Pegfilgrastim) and Biosimilar Company Evaluation Quadrant
Table 22. World Neulasta (Pegfilgrastim) and Biosimilar Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Neulasta (Pegfilgrastim) and Biosimilar Production Site of Key Manufacturer
Table 24. Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Type Footprint
Table 25. Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Application Footprint
Table 26. Neulasta (Pegfilgrastim) and Biosimilar Competitive Factors
Table 27. Neulasta (Pegfilgrastim) and Biosimilar New Entrant and Capacity Expansion Plans
Table 28. Neulasta (Pegfilgrastim) and Biosimilar Mergers & Acquisitions Activity
Table 29. United States VS China Neulasta (Pegfilgrastim) and Biosimilar Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Neulasta (Pegfilgrastim) and Biosimilar Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Neulasta (Pegfilgrastim) and Biosimilar Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share (2018-2023)
Table 37. China Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share (2018-2023)
Table 42. Rest of World Based Neulasta (Pegfilgrastim) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share (2018-2023)
Table 47. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Neulasta (Pegfilgrastim) and Biosimilar Production by Type (2018-2023) & (K Units)
Table 49. World Neulasta (Pegfilgrastim) and Biosimilar Production by Type (2024-2029) & (K Units)
Table 50. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Type (2018-2023) & (USD Million)
Table 51. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Type (2024-2029) & (USD Million)
Table 52. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Neulasta (Pegfilgrastim) and Biosimilar Production by Application (2018-2023) & (K Units)
Table 56. World Neulasta (Pegfilgrastim) and Biosimilar Production by Application (2024-2029) & (K Units)
Table 57. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Application (2018-2023) & (USD Million)
Table 58. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Application (2024-2029) & (USD Million)
Table 59. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Amgen Basic Information, Manufacturing Base and Competitors
Table 62. Amgen Major Business
Table 63. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 64. Amgen Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Amgen Recent Developments/Updates
Table 66. Amgen Competitive Strengths & Weaknesses
Table 67. Viatris Basic Information, Manufacturing Base and Competitors
Table 68. Viatris Major Business
Table 69. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 70. Viatris Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Viatris Recent Developments/Updates
Table 72. Viatris Competitive Strengths & Weaknesses
Table 73. Coherus Basic Information, Manufacturing Base and Competitors
Table 74. Coherus Major Business
Table 75. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 76. Coherus Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Coherus Recent Developments/Updates
Table 78. Coherus Competitive Strengths & Weaknesses
Table 79. Novartis Basic Information, Manufacturing Base and Competitors
Table 80. Novartis Major Business
Table 81. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 82. Novartis Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Novartis Recent Developments/Updates
Table 84. Novartis Competitive Strengths & Weaknesses
Table 85. Pfizer Basic Information, Manufacturing Base and Competitors
Table 86. Pfizer Major Business
Table 87. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 88. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Pfizer Recent Developments/Updates
Table 90. Pfizer Competitive Strengths & Weaknesses
Table 91. Amneal Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 92. Amneal Pharmaceutical Major Business
Table 93. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 94. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 95. Amneal Pharmaceutical Recent Developments/Updates
Table 96. Fresenius Kabi Basic Information, Manufacturing Base and Competitors
Table 97. Fresenius Kabi Major Business
Table 98. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product and Services
Table 99. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 100. Global Key Players of Neulasta (Pegfilgrastim) and Biosimilar Upstream (Raw Materials)
Table 101. Neulasta (Pegfilgrastim) and Biosimilar Typical Customers
Table 102. Neulasta (Pegfilgrastim) and Biosimilar Typical Distributors
LIST OF FIGURES
Figure 1. Neulasta (Pegfilgrastim) and Biosimilar Picture
Figure 2. World Neulasta (Pegfilgrastim) and Biosimilar Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Neulasta (Pegfilgrastim) and Biosimilar Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029) & (K Units)
Figure 5. World Neulasta (Pegfilgrastim) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 6. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Region (2018-2029)
Figure 7. World Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Region (2018-2029)
Figure 8. North America Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029) & (K Units)
Figure 9. Europe Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029) & (K Units)
Figure 10. China Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029) & (K Units)
Figure 11. Japan Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029) & (K Units)
Figure 12. Neulasta (Pegfilgrastim) and Biosimilar Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 15. World Neulasta (Pegfilgrastim) and Biosimilar Consumption Market Share by Region (2018-2029)
Figure 16. United States Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 17. China Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 18. Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 19. Japan Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 20. South Korea Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 22. India Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Neulasta (Pegfilgrastim) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Neulasta (Pegfilgrastim) and Biosimilar Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Neulasta (Pegfilgrastim) and Biosimilar Markets in 2022
Figure 26. United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share 2022
Figure 30. China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share 2022
Figure 32. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Type in 2022
Figure 34. Brand
Figure 35. Biosimilar
Figure 36. World Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Type (2018-2029)
Figure 37. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Type (2018-2029)
Figure 38. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Application in 2022
Figure 41. Hospital
Figure 42. Pharmacy
Figure 43. Other
Figure 44. World Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Application (2018-2029)
Figure 45. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Application (2018-2029)
Figure 46. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Neulasta (Pegfilgrastim) and Biosimilar Industry Chain
Figure 48. Neulasta (Pegfilgrastim) and Biosimilar Procurement Model
Figure 49. Neulasta (Pegfilgrastim) and Biosimilar Sales Model
Figure 50. Neulasta (Pegfilgrastim) and Biosimilar Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
Figure 1. Neulasta (Pegfilgrastim) and Biosimilar Picture
Figure 2. World Neulasta (Pegfilgrastim) and Biosimilar Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Neulasta (Pegfilgrastim) and Biosimilar Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029) & (K Units)
Figure 5. World Neulasta (Pegfilgrastim) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 6. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Region (2018-2029)
Figure 7. World Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Region (2018-2029)
Figure 8. North America Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029) & (K Units)
Figure 9. Europe Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029) & (K Units)
Figure 10. China Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029) & (K Units)
Figure 11. Japan Neulasta (Pegfilgrastim) and Biosimilar Production (2018-2029) & (K Units)
Figure 12. Neulasta (Pegfilgrastim) and Biosimilar Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 15. World Neulasta (Pegfilgrastim) and Biosimilar Consumption Market Share by Region (2018-2029)
Figure 16. United States Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 17. China Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 18. Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 19. Japan Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 20. South Korea Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 22. India Neulasta (Pegfilgrastim) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Neulasta (Pegfilgrastim) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Neulasta (Pegfilgrastim) and Biosimilar Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Neulasta (Pegfilgrastim) and Biosimilar Markets in 2022
Figure 26. United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Neulasta (Pegfilgrastim) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share 2022
Figure 30. China Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Neulasta (Pegfilgrastim) and Biosimilar Production Market Share 2022
Figure 32. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Type in 2022
Figure 34. Brand
Figure 35. Biosimilar
Figure 36. World Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Type (2018-2029)
Figure 37. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Type (2018-2029)
Figure 38. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Neulasta (Pegfilgrastim) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Application in 2022
Figure 41. Hospital
Figure 42. Pharmacy
Figure 43. Other
Figure 44. World Neulasta (Pegfilgrastim) and Biosimilar Production Market Share by Application (2018-2029)
Figure 45. World Neulasta (Pegfilgrastim) and Biosimilar Production Value Market Share by Application (2018-2029)
Figure 46. World Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Neulasta (Pegfilgrastim) and Biosimilar Industry Chain
Figure 48. Neulasta (Pegfilgrastim) and Biosimilar Procurement Model
Figure 49. Neulasta (Pegfilgrastim) and Biosimilar Sales Model
Figure 50. Neulasta (Pegfilgrastim) and Biosimilar Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
